$28.47
Insights on Genmab A/s
Revenue is down for the last 2 quarters, 4.74B → 4.67B (in $), with an average decrease of 1.4% per quarter
Netprofit is down for the last 2 quarters, 2.12B → 640.0M (in $), with an average decrease of 69.9% per quarter
In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 83.1%
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 269.8%
1.32%
Downside
Day's Volatility :2.14%
Upside
0.84%
7.55%
Downside
52 Weeks Volatility :38.39%
Upside
33.36%
Period | Genmab A/s | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 3.37% | 2.0% | 0.0% |
6 Months | -3.25% | 11.7% | 0.0% |
1 Year | -31.26% | 5.8% | 1.3% |
3 Years | -23.08% | 14.2% | -22.1% |
Market Capitalization | 18.8B |
Book Value | $483.85 |
Earnings Per Share (EPS) | 0.94 |
PE Ratio | 30.82 |
PEG Ratio | 1.27 |
Wall Street Target Price | 41.25 |
Profit Margin | 26.42% |
Operating Margin TTM | 35.7% |
Return On Assets TTM | 10.17% |
Return On Equity TTM | 14.78% |
Revenue TTM | 16.5B |
Revenue Per Share TTM | 25.22 |
Quarterly Revenue Growth YOY | -8.9% |
Gross Profit TTM | 14.6B |
EBITDA | 5.6B |
Diluted Eps TTM | 0.94 |
Quarterly Earnings Growth YOY | 0.25 |
EPS Estimate Current Year | 1.1 |
EPS Estimate Next Year | 1.5 |
EPS Estimate Current Quarter | 4.02 |
EPS Estimate Next Quarter | 2.7 |
What analysts predicted
Upside of 44.89%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 463.5M | ↑ 27.89% |
Net Income | 225.5M | ↑ 33.4% |
Net Profit Margin | 48.66% | ↑ 2.01% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 804.5M | ↑ 77.38% |
Net Income | 324.8M | ↑ 47.13% |
Net Profit Margin | 40.37% | ↓ 8.29% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.7B | ↑ 88.43% |
Net Income | 786.5M | ↑ 119.67% |
Net Profit Margin | 47.06% | ↑ 6.69% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.3B | ↓ 16.11% |
Net Income | 450.2M | ↓ 37.85% |
Net Profit Margin | 34.86% | ↓ 12.2% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.1B | ↑ 72.07% |
Net Income | 784.8M | ↑ 84.38% |
Net Profit Margin | 37.36% | ↑ 2.5% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.4B | ↑ 12.87% |
Net Income | 644.5M | ↓ 20.18% |
Net Profit Margin | 26.42% | ↓ 10.94% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 540.2M | ↑ 29.25% |
Net Income | 341.3M | ↑ 36.54% |
Net Profit Margin | 63.18% | ↑ 3.38% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 752.4M | ↑ 27.89% |
Net Income | 84.1M | ↓ 77.38% |
Net Profit Margin | 11.17% | ↓ 52.01% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 417.8M | ↓ 45.4% |
Net Income | 33.1M | ↓ 61.3% |
Net Profit Margin | 7.92% | ↓ 3.25% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 615.3M | ↑ 47.09% |
Net Income | 198.9M | ↑ 500.44% |
Net Profit Margin | 32.32% | ↑ 24.4% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.7B | ↑ 13.01% |
Net Income | 2.1B | ↑ 56.89% |
Net Profit Margin | 44.88% | ↑ 12.56% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 692.7M | ↓ 1.39% |
Net Income | 94.8M | ↓ 69.94% |
Net Profit Margin | 13.68% | ↓ 31.2% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 28.14% |
Total Liabilities | 68.4M | ↑ 35.04% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.3B | ↑ 78.99% |
Total Liabilities | 164.3M | ↑ 145.39% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 3.5B | ↑ 39.61% |
Total Liabilities | 334.2M | ↑ 84.49% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 3.7B | ↑ 16.48% |
Total Liabilities | 370.1M | ↑ 20.23% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 4.4B | ↑ 22.95% |
Total Liabilities | 408.4M | ↑ 16.7% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 5.2B | ↑ 16.55% |
Total Liabilities | 544.8M | ↑ 29.68% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 4.1B | ↑ 11.68% |
Total Liabilities | 532.6M | ↑ 34.57% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 4.4B | ↓ 1.33% |
Total Liabilities | 408.4M | ↓ 29.59% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 4.4B | ↑ 0.38% |
Total Liabilities | 469.1M | ↑ 12.94% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 4.7B | ↑ 5.21% |
Total Liabilities | 472.4M | ↑ 0.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 35.2B | ↑ 10.19% |
Total Liabilities | 4.1B | ↑ 28.02% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 5.2B | ↑ 0.14% |
Total Liabilities | 544.8M | ↓ 10.83% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 155.5M | ↓ 36.14% |
Investing Cash Flow | -272.4M | ↑ 166.34% |
Financing Cash Flow | -10.9M | ↓ 132.99% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 198.8M | ↑ 30.67% |
Investing Cash Flow | -297.3M | ↑ 11.53% |
Financing Cash Flow | 548.8M | ↓ 5262.13% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↑ 385.14% |
Investing Cash Flow | -388.6M | ↑ 18.56% |
Financing Cash Flow | 11.7M | ↓ 98.06% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 339.2M | ↓ 65.37% |
Investing Cash Flow | -146.3M | ↓ 59.12% |
Financing Cash Flow | -63.9M | ↓ 691.55% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 563.1M | ↑ 75.58% |
Investing Cash Flow | -397.4M | ↑ 187.3% |
Financing Cash Flow | -113.6M | ↑ 87.86% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 260.1M | ↑ 105.21% |
Investing Cash Flow | -182.7M | ↑ 139.93% |
Financing Cash Flow | -84.9M | ↑ 200.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 57.3M | ↓ 79.78% |
Investing Cash Flow | -19.6M | ↓ 90.16% |
Financing Cash Flow | 18.9M | ↓ 120.4% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 473.6M | ↑ 712.81% |
Investing Cash Flow | -268.7M | ↑ 1249.26% |
Financing Cash Flow | -89.5M | ↓ 566.41% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 63.9M | ↓ 86.52% |
Investing Cash Flow | -269.0M | ↑ 0.0% |
Financing Cash Flow | 1.0M | ↓ 101.15% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.0B | ↑ 367.2% |
Investing Cash Flow | 1.0B | ↓ 154.93% |
Financing Cash Flow | 20.0M | ↑ 185.71% |
Sell
Neutral
Buy
Genmab A/s is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Genmab A/s | -4.74% | -3.25% | -31.26% | -23.08% | 57.1% |
Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
Vertex Pharmaceuticals Incorporated | -2.67% | 11.53% | 21.99% | 86.62% | 131.89% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Genmab A/s | 30.82 | 30.82 | 1.27 | 1.1 | 0.15 | 0.1 | NA | 483.85 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Genmab A/s | Buy | $18.8B | 57.1% | 30.82 | 26.42% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 131.89% | 28.81 | 36.68% |
AllianceBernstein L.P.
BlackRock Inc
Capital Research & Mgmt Co - Division 3
Harding Loevner L.P.
Wellington Management Company LLP
Renaissance Technologies Corp
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.
Organization | Genmab A/s |
Employees | 2204 |
CEO | Dr. Jan G.J. van de Winkel Ph.D. |
Industry | Health Technology |
Molina Healthcare, Inc.
$28.47
-0.32%
Icici Bank Ltd.
$28.47
-0.32%
Globalfoundries Inc.
$28.47
-0.32%
Lpl Financial Holdings Inc.
$28.47
-0.32%
Ares Capital Corporation
$28.47
-0.32%
Cognizant Technology Solutions Corp.
$28.47
-0.32%
Illinois Tool Works Inc.
$28.47
-0.32%
Schwab Us Large-cap Growth Etf
$28.47
-0.32%
Union Pacific Corporation
$28.47
-0.32%